Clinical Trial Update: Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study assessing safety and pharmacokinetics of AVE9633 as a single agent in adults with relapsed/refractory CD33-positive acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AVE9633

Snippet

Sponsor: Sanofi | Conditions: Myeloid Leukemia | Phase 1 | Status: TERMINATED